New medicine to treat paediatric low-grade glioma

View source ↗

Summary

EMA approved a new medicine, Ojemda, to treat paediatric low-grade glioma in children aged 6 months and older, including tumours with BRAF alterations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• OJEMDA (TOVORAFENIB)

Snippet

Ojemda addresses unmet need for patients aged 6 months and older with paediatric brain tumour with BRAF alterations